In 2022, the Russian pharmaceutical market witnessed a growth of 4.9%, reaching a market value of $31.9 billion, amidst increased demand for drugs and medical solutions driven by the rising prevalence of acute and chronic diseases. This upward trend is anticipated to continue, with forecasts predicting the market value to escalate to $40 billion by 2027, marking a 25.4% increase from 2022.

Accounting for 9% of the European pharmaceutical market value, Russia’s pharmaceutical sector is characterized by intense competition among large international corporations like Novartis, Sanofi, Bayer, and Les Laboratoires Servier, and smaller generic companies vying for drug approvals. The presence of these major players, coupled with significant research and development investments, underscores a competitive landscape where rivalry is mitigated by strong market growth.